Interim report January-June 2016

January - June 2016

  · Net sales amounted to SEK 2 208 million (1 742), an increase of 27 %
  · EBITDA increased by 20 % and amounted to SEK 376 million (314) giving an
EBITDA margin of 17.0 % (18.0)
  · Operating profit (EBIT) amounted to SEK 218 million (198)
  · Profit after tax amounted to SEK 108 million (189: last year included a
financial capital gain of SEK 46.6 million), giving a net margin of 4.9 % (10.9)
  · Earnings per share amounted to SEK 2.14 (4.22), after dilution 2.13 (4.22)
  · Cash flow from operating activities was SEK 78.6 million (201)
  · Net debt to Equity was 0.4 (0.4)

Key figures

                 Apr       change      Jan - Jun     change     Jul 15
              - Jun

SEK million   2016   2015  in %    2016   2015       in %    - Jun 16   2015
Net sales     1 235  868   42.2    2 208  1 742      26.8    3 856      3 389
Net sales     1 239  856   42.6    2 216  1 709      27.3               3 344
(CER) 1/
EBITDA 1/     240    156   54.0    376    314        19.9    572        510
EBIT 1/       150    98    61.3    218    198        14.4    303        274
EBITDA        19.4   17.9          17.0   18.0               14.8       15.0
margin (%)
1/
Earnings per  1.67   1.50  23.3    2.14   4.22       -45.2   5.94       4.72
share
Return on                          3.5    11.4                          8.8
equity (%)
1/
Equity per                          91.9  59.3                          59.2
share (SEK)
1/
Equity ratio                       51.1   49.7                          48.1
(%) 1/
Net debt 1/                        1 807  1 001                         1 183
Net debt to                        0.4    0.4                           0.4
Equity 1/
Net debt to                        3.2    2.0                           2.3
EBITDA 1/

1/ APM: Alternative Performance Measures, see financial definitions after note 5

Thomas Eldered, CEO:
“With a sales increase of 42 percent we recorded all-time high sales for the
quarter. For the first time we had sales in excess of SEK 1 billion, and this
even without the SEK 231 million contribution from recent acquisitions. Sales
growth during the quarter, excluding acquisitions was 16 percent in local
currencies. Sales of the volatile tender product Thyrosafe and from the new
contract in Kaysersberg, France as well as phasing of revenues from the first
quarter contributed significantly to the sales increase.  A packaging-only
contract, discontinued in Q3 2015, lower reference prices in Portugal and lower
sales in the UK of certain high-margin own products had a negative impact.

EBITDA for the quarter increased 54 percent to SEK 240 million and EBITDA-margin
increased sequentially to 19.4 percent, the highest quarterly margin ever for
Recipharm. Excluding acquisitions, completed during the last twelve months,
EBITDA still reached an all-time high for a quarter. In addition to the sales
growth, a price adjustment related to the first quarter this year had a positive
impact on EBITDA. Implementation of the cost and efficiency program in Swedish
operations started to impact EBITDA positively somewhat ahead of plan.

We continued to take important steps to strengthen Recipharm and to support
achievement of our long-term targets. Completed acquisitions during the quarter
of Indian Nitin Lifesciences Ltd, Swedish Kemwell AB and US Cirrus
Pharmaceuticals Inc together with Italian Mitim Srl, acquired in February,
performed according to our expectations and integration activities progressed in
-line with plan. Together with the acquisition of Kemwell’s pharmaceutical
business in India, with expected authority approvals in Q4 this year, we have
now strengthened our synergistic business model and will align development and
manufacturing services globally. Our high-performing European operations, highly
efficient Indian capabilities and US bridgehead, providing access to our network
for small and midsize US customers, is creating a leading global setup providing
valuable solutions to our customers. We continue to make expansion investments
in the Sterile Liquids segment, in particular to meet the strong demand we see
for our lyophilisation services and blow-fill-seal technology.

As expected we comply with our EBITDA-margin and Net debt to Equity targets.
Going forward I expect our growth-driving strategies, including executing on
further acquisition opportunities, to continue to deliver. The markets we
operate in remain competitive but at the same time providing both growth and
many opportunities. With our global reach and attractive value proposition to
our customers I’m confident that we will reach our long term growth targets set
to 2020. We were pleased with the support showed by our shareholders in the
recently completed rights issue and we are very well placed to continue to
explore the opportunities we see in the market.”

The complete interim report is attached through the link at the end of the press
release.

The company invites investors, analysts and media to a web conference with a
presentation (in English) on 22 July 10:00 am CET where CEO Thomas Eldered and
CFO Björn Westberg will present and comment on the interim report and answer
questions.

To participate in the web conference, please use the below link:

http://edge.media-server.com/m/p/ufdsgyft

Questions may be submitted by dialing below telephone numbers or by typing them
in the Q&A box during the conference. If you don’t wish to ask questions by
telephone you only need to participate through the link above.
From Sweden: + 46 8 505 963 06
From Denmark: + 45 354 45597
From Finland: + 358 9 8171 0317
From France: + 33 29092 0977
From Germany: + 49 30 211 510 067
From India: + 91 226187 51 03
From Italy: + 39 2 3604 67 98
From Norway: + 47 235 00 559
From Portugal: + 35 210 609104
 From Spain: + 34 911 143 608
From Switzerland: + 41 44 5800083
From the UK: + 44 203 139 48 30
From the USA: + 1 718 873 90 77
Pin code for participants:
44823539#

For more information, please visit www.recipharm.com or contact:
Thomas Eldered, CEO, +46 8 602 52 10
Björn Westberg, CFO, ir@recipharm.com, +46 8 602 46 20

This information is published in accordance with the Swedish Securities Market
Act, the Swedish Financial Instruments Trading Act and/or the regulations of
NASDAQ Stockholm. This information was submitted for publication on 22 July 2016
at 07:45 am CET.

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry employing some 3,500 employees.
Recipharm offers manufacturing services of pharmaceuticals in various dosage
forms, production of clinical trial material and APIs, and pharmaceutical
product development. Recipharm manufactures several hundred different products
to customers ranging from Big Pharma to smaller research- and development
companies. Recipharm’s turnover is approximately SEK 5.0 billion and the Company
operates development and manufacturing facilities in France, Germany, India,
Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered
in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq
Stockholm.
For more information on Recipharm and our services, please visit
www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52
00, Fax 46 8 81 87 03
www.recipharm.com